PIH Health

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Colorectal cancer2 trials
• Triple-negative breast cancer2 trials
• Lung cancer1 trial
• Neuroblastoma1 trial
• Sarcoma1 trial

Phase

• Phase 23 trials
• Phase 32 trials

Status

• Active, not recruiting3 trials
• Completed1 trial
• Terminated1 trial

Lead sponsor

• Cardiff Oncology2 trials
• Daiichi Sankyo1 trial
• G1 Therapeutics, Inc.1 trial
• NSABP Foundation Inc1 trial

Running trials

• Active, not recruiting

  Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

  NCT06106308· Phase 2· Cardiff Oncology· Source

• Active, not recruiting

  Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

  NCT04656652· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

  NCT03281954· Phase 3· NSABP Foundation Inc· Source

Closed trials

• Completed

  Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

  NCT05593328· Phase 2· Cardiff Oncology· Source

• Terminated

  Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

  NCT05113966· Phase 2· G1 Therapeutics, Inc.· Source